Contact
searchSearch
HMP Global
Login

July/August 2018

Column

Editor's Page
Balancing Costs and Patient Safety When Navigating New Regulations
08/22/2018
As new and exciting advancements in cancer drugs and care are made, updated guidance and regulations must follow. Oncologists and other stakeholders must keep up with the latest rules and regulations in order to...
As new and exciting advancements in cancer drugs and care are made, updated guidance and regulations must follow. Oncologists and other stakeholders must keep up with the latest rules and regulations in order to...
As new...
08/22/2018
Journal of Clinical Pathways
PATIENT PERSPECTIVE
Talking About Costs of Care During Shared Decision Making—Part One: The Problem
08/22/2018
In Part 1 of this 2-part column series on shared decision making, we discuss the need for health care teams to create a safe and inviting environment for patients to talk about financial concerns and questions...
In Part 1 of this 2-part column series on shared decision making, we discuss the need for health care teams to create a safe and inviting environment for patients to talk about financial concerns and questions...
In...
08/22/2018
Journal of Clinical Pathways
Clinical Pathways GPS
Communicating More Through Clinical Pathways to Advance Value-Based Health Care
08/22/2018
The Food and Drug Administration (FDA) recently published guidance that clarifies how pharmaceutical manufacturers can share product information with payers while remaining compliant with FDA rules on...
The Food and Drug Administration (FDA) recently published guidance that clarifies how pharmaceutical manufacturers can share product information with payers while remaining compliant with FDA rules on...
The...
08/22/2018
Journal of Clinical Pathways
Counterpoint
CAR-T Therapies: Placing Patient Safety First
08/22/2018
The commercial success and ability of eligible patients to receive chimeric antigen receptor T-cell (CAR-T) therapies depend on optimizing the logistics of delivering this transformational treatment platform. One...
The commercial success and ability of eligible patients to receive chimeric antigen receptor T-cell (CAR-T) therapies depend on optimizing the logistics of delivering this transformational treatment platform. One...
The...
08/22/2018
Journal of Clinical Pathways
Viewpoint
CMS Sets CAR-T Reimbursement Levels—Where Should the Patient Be Treated?
08/22/2018
The Centers for Medicare and Medicaid Services (CMS) just announced their reimbursement level for the new chimeric antigen receptor T-cell (CAR-T) products. While it is in line with their standard reimbursement...
The Centers for Medicare and Medicaid Services (CMS) just announced their reimbursement level for the new chimeric antigen receptor T-cell (CAR-T) products. While it is in line with their standard reimbursement...
The...
08/22/2018
Journal of Clinical Pathways

News

Conference Coverage
ESMO World Congress on Gastrointestinal Cancer 2018
08/22/2018
JCP Editors
With over 18,000 members representing oncology professionals from over 150 countries, the European Society for Medical Oncology (ESMO) is the leading professional organization for medical oncology. ESMO’s educational...
With over 18,000 members representing oncology professionals from over 150 countries, the European Society for Medical Oncology (ESMO) is the leading professional organization for medical oncology. ESMO’s educational...
With...
08/22/2018
Journal of Clinical Pathways

Insights

Interview
Wolters Kluwer Clinical Decision-Making Tool Offers Evidence-Backed Support
08/22/2018
JCP Editors
Wolters Kluwer recently launched UpToDate Advanced, a new evidenced-backed tool to help standardize clinical decisions and reduce costs. This new tool makes use of the UpToDate Pathways, which are built upon the...
Wolters Kluwer recently launched UpToDate Advanced, a new evidenced-backed tool to help standardize clinical decisions and reduce costs. This new tool makes use of the UpToDate Pathways, which are built upon the...
...
08/22/2018
Journal of Clinical Pathways

Feature

Research Reports
KRAS/RAS Testing Is Associated With Reduced Risk of Treatment Discontinuation in Patients With Metastatic Colorectal Cancer
08/22/2018
Abstract: Current clinical guidelines recommend that all patients with metastatic colorectal cancer (mCRC) have tumor tissue genotyped for RAS mutations. This study aimed to evaluate patient characteristics and...
Abstract: Current clinical guidelines recommend that all patients with metastatic colorectal cancer (mCRC) have tumor tissue genotyped for RAS mutations. This study aimed to evaluate patient characteristics and...
...
08/22/2018
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Volume 4

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use